TruSight Oncology 500 (TSO500)
Pan-cancer next-generation sequencing assay for biomarker identification and comprehensive genomic profiling across 523 genes
A Hybrid-Capture Approach for Target Enrichment of 523 Genes Across Various Tumor Types
Gain an expansive view of your solid tumor samples by targeting 523 cancer-related genes using the TruSight Oncology 500 assay. Not only does this assay identify all relevant variants (SNVs, insertions, deletions, CNVs, gene fusions, and transcript variants) across various tumor types, but it also reports tumor mutational burden (TMB) and microsatellite instability (MSI) scores.
Our comprehensive genomic panel has advantages over individual biomarker assays in its ability to detect multiple biomarkers with one test, saving time, money, and samples. IQVIA Laboratories can meet your profiling needs by leveraging trusted technology from Illumina® in combination with our global laboratory network and expert support team.
An Efficient, Reliable Solution for Non-Invasive Tumor Characterization
Minimal input, extensive results
Obtain full exon coverage of 522 out of 523 genes using as little as 3 mL of plasma, 20-30 ng of cfDNA, or 10 mL of whole blood. TSO500 ctDNA can detect biomarkers without the need of a matched normal sample.
Simple, cost-effective workflow
Detect multiple biomarkers with a single assay to save time, money, and samples. The distributable kit enables global implementation.
Confident variant detection
Obtain a high-resolution view of variants enabled by TSO500 ctDNA’s hybrid-capture chemistry and unique molecular indices (UMIs).
Measurement of key immuno-oncology biomarkers
Gain insight into TMB score and MSI score in addition to variant calls. TruSight Oncology 500 ctDNA can reproducibly assess TMB.
Expansive services enabled by our global network
Our centralized, scientific operational oversight combined with our global laboratory footprint enable comprehensive, large-scale trial support. We enable clinical development support irrespective of geography.
Flexible customization to satisfy specific needs
We work with you to understand your specific needs, and our team provides cost-effective recommendations from custom assay development to specialized bioinformatics support.
TSO500 ctDNA Variant Detection
TSO500 Assay Comparison
Deep Sequencing Enabled by IQVIA Laboratories Subject Matter Expertise
Feel confident in your results with the trusted Illumina® software pipeline. Our software teams validate the most up-to-date software to ensure you are receiving optimal results. IQVIA Laboratories can develop custom reporting and filtering to meet your specific research needs. IQVIA Laboratories was one of the earliest adopters of DRAGEN™. Our technical support teams help you understand your deep sequencing data with our superior bioinformatics knowledge.
Deliverables
IQVIA Laboratoriesprovides a text-delimited, combined variant output file for all biomarkers
- QC Metrics
- CNV Outputs
- RNA Splice Variants
- RNA Fusion Report
- Genomic VCFs (SNVs & Indels)
- Variant Call Annotations
- MSI Scores
- TMB Scores
- FASTQs
- BAMs
Regulatory
Validated up to CAP/CLIA standards
IQVIA Laboratories offers this TSO500 assay at multiple regulatory levels, from Research Use Only (RUO) to Good Clinical Practices (GCP) to CAP/CLIA, depending on the intended use of the assay by our client. Please reach out to our IQVIA Laboratories Genomics Business Development team to discuss your intended use so we can better guide which regulatory level is most appropriate for your clinical or research program(s).
Supporting Studies Around the World
Our centralized, scientific, and operational oversight combined with our global laboratory footprint enables comprehensive, large-scale trial support. You will be supported every step of the way by our scientific project management team who will work with you to understand the most cost-effective recommendations to meet your specific needs. We are committed to transparency so you can feel confident in our promises of quality and timely delivery. We can expert support team can meet your research needs from nearly anywhere in the world with our genomic centers in the United States, China, United Kingdom, and Singapore.
Learn More About TSO500 with IQVIA
Posters
- TMB Standardization by Alignment to Reference Standards
- Panel-based TMB Analysis of Matched Tumor and Plasma Specimens Using Illumina’s TSO500 NGS Assay
- Comprehensive Genomic Profiling in FFPE Tissue Sample using TruSight Oncology 500 Assay
Presentations
- Approaches to Demonstrating Commutability of Various NGS Reference Standards for Targeted ctDNA Analysis
- Analytical Validation of Illumina’s TSO500 ctDNA Assay
Whitepaper
Fact Sheets
-
Webinars
- Bridging the Gap in Liquid Biopsies with CTCs and ctDNA
- Comprehensive Genomic Profiling from Liquid Biopsy Samples: Clinical Trial Considerations
Podcasts
- The Standardization of TMB by Alignment to Reference Standards
- Liquid Biopsy Collection in Clinical Development Programs
Press Release
Video
Simplify Your Work
Request a Quote
Request a quote today to discover how TSO500 with IQVIA can advance your research.
Ship Samples
Ship your samples to one of our global genomic laboratory centers.
Get Results
Obtain in-depth data revealing insights into your solid tumor samples.
Related Services
Clinical Genomics Laboratory Services
Learn moreNext Generation Sequencing Services
Learn moreMicrosatellite Instability (MSI) Assay
Learn moreImmune Landscape Signatures
Learn moreTumor Mutational Burden (TMB) Analysis
Learn moreTruSight Oncology 500 Plasma Assay
Learn moreTumor Mutational Burden (TMB) Analysis
Learn moreRNA Sequencing and DNA Sequencing Services
Learn moreClinical Genomics Laboratory Technology Platforms
Learn moreBioinformatics
Learn moreCentral Laboratory Services
Learn moreRelated Insights
Reproducibility Challenges in an era of Massive Data
Presented at the MCBIOS & MAQC 2021 Joint Conference
A Verified Genomic Reference Sample for Assessing Performance of Cancer Panels Detecting Small Variants of Low Allele Frequency
Presented at the MCBIOS & MAQC 2021 Joint Conference
Unexpected Impacts to Library Complexity After DNA and RNA Library Preparation in Illumina Next Generation Sequencing
Presented at the MCBIOS & MAQC 2021 Joint Conference
Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy
Gene expression and analysis for detection of 38 Immune Landscape Signatures
Using Gene Signature Methodologies to Strengthen Immuno-Oncology Trials
Genomic technologies that empower and enhance immuno-oncology trials
Laboratory Solutions for Hepatitis B (HBV) Clinical Trials
Insight brief by Joseph Sebastian, Ph.D., Scientific Advisor, Infectious & Liver Diseases
Enabling blood sample prep for single cell sequencing in clinical research
The Role of Genomics in Clinical Trials with Patrick Hurban
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
Learn about what we do and our commitment to innovation
Evaluating and Implementing SARS-CoV-2 PCR Tests for Diagnostic and Clinical Trial Use
AAPS 2020 COVID-19 Workshop: Current Pharmaceutical Developments for Cures and Prevention